EGFR and neoplasm: Targeting a tumor-restricted target such as EGFRvIII in glioblastoma via the CAR component drives localization of the cell product to the tumor enabling localized release of a TCE targeting a more homogenously expressed, yet more broadly expressed, second target such as IL13Ra2 or EGFR (92–94).